Bionano Reports Third Quarter 2026 Results and Provides a Business Update
Key Highlights
- ➤Q3 revenue $8.3 million, up 12% year over year
- ➤Consumables revenue $4.7 million, up 24% year over year
- ➤Flowcell sales 9,870, up 18% from 8,390
- ➤Gross margin 48%, up from 46% year over year
- ➤2026 revenue guidance reaffirmed at $31 million to $33 million
Expert Statements
Al Luderer, Chairman and interim chief executive officer of Bionano Genomics
“Our third quarter results reflect the momentum building across our business and the broader genomics community, further accelerating the adoption of optical genome mapping (OGM) in clinical and commercial settings.”
Al Luderer, Chairman and interim chief executive officer of Bionano Genomics
“Coverage and regulatory progress this quarter helped build a clearer reimbursement pathway for OGM-based testing, which we expect to support broader clinical adoption over time.”
Al Luderer, Chairman and interim chief executive officer of Bionano Genomics
“Leading academic cancer centers are also bringing OGM into their clinical laboratories, expanding the base of routine users that drives utilization of our products.”
Al Luderer, Chairman and interim chief executive officer of Bionano Genomics
“The evidence base also continued to grow, with new independent peer-reviewed studies demonstrating the value of OGM across a range of disorders.”
Al Luderer, Chairman and interim chief executive officer of Bionano Genomics
“We are well positioned to turn this momentum into sustained growth in 2027 and beyond.”
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2026.
“Our third quarter results reflect the momentum building across our business and the broader genomics community, further accelerating the adoption of optical genome mapping (OGM) in clinical and commercial settings,” commented Al Luderer, Ph.D., chairman and interim chief executive officer of Bionano. “Coverage and regulatory progress this quarter helped build a clearer reimbursement pathway for OGM-based testing, which we expect to support broader clinical adoption over time. Leading academic cancer centers are also bringing OGM into their clinical laboratories, expanding the base of routine users that drives utilization of our products. The evidence base also continued to grow, with new independent peer-reviewed studies demonstrating the value of OGM across a range of disorders. We are well positioned to turn this momentum into sustained growth in 2027 and beyond.”
Get started
Create a free account to read the full story.